$Dramatic decline in prostate‐specific antigen by withdrawal of estramustine phosphate in hormone refractory prostate cancer$

Dramatic decline in prostate‐specific antigen by withdrawal of estramustine phosphate in hormone refractory prostate cancer

Prostate‐specific antigen (PSA) decline after discontinuation of estramustine phosphate (EMP) is extremely rare. We report a case with dramatic PSA decline after withdrawal of EMP. A patient with prostate cancer had been treated with luteinizing hormone‐releasing hormone and EMP. After refractory, E...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	International journal of urology 2006-07, Vol.13 (7), p.1019-1021
Hauptverfasser:	KOBAYASHI, MIZUKI, KURAMOTO, HIROSHI, OTA, JUNICHIRO, FUJIMOTO, NAOHIRO
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged, 80 and over antiandrogen withdrawal syndrome Antineoplastic Agents, Hormonal Biomarkers, Tumor - blood Disease Progression Drug Resistance, Neoplasm Estramustine - therapeutic use estramustine phosphate Follow-Up Studies hormone refractory Humans Male prostate cancer prostate specific antigen Prostate-Specific Antigen - blood Prostatic Neoplasms - blood Prostatic Neoplasms - drug therapy Treatment Refusal
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!